Official statements from major regulatory bodies like FDA, EMA, etc.

Global Leaders Back Lenacapavir, Gilead's HIV Drug with 100% Efficacy in Phase 3 Testing, Single Shot Every Year

Dec 15, 2024, 03:44 PM

Global leaders are uniting to support the development of an injectable medication aimed at eradicating HIV. Gilead Sciences announced plans to initiate Phase 3 testing for Lenacapavir, a drug that could potentially prevent HIV infection with just a single annual injection. This medication has been recognized as a significant scientific advancement, with reports highlighting its remarkable efficacy. A large trial conducted in June involving African adolescent girls and young women demonstrated that the treatment reduced HIV infections to zero, achieving an efficacy rate of 100%. This finding was corroborated by a subsequent trial conducted across multiple regions three months later, reinforcing the drug's potential impact in the fight against HIV/AIDS.